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Introduction
Testicular cancer is typically a disease of young men (1) with 
multiple available treatment options. Therapeutic pathways 
depend on disease stage and pathologic features and 
typically result in high survival rates. Treatments include 
active surveillance, retroperitoneal lymph node dissection 
(RPLND), primary chemotherapy, and radiotherapy 
(seminoma only) (2) and choice of therapy is often based 
on the patient’s perception of treatment toxicities. Surgery 
has typically been utilized as primary treatment for clinical 
stage (CS) I non-seminomatous germ cell tumor (NSGCT) 
as well as for post-chemotherapy residual masses. 
When considering a surgical approach, open RPLND 
(O-RPLND) has been long considered the standard of 
care and the basis for comparison of alternative surgical 
techniques. Access for O-RPLND, however, historically has 
involved a xiphoid to pubis abdominal wall incision to allow 
access to the entire retroperitoneum and can be associated 
with significant morbidity. Given the pain and morbidity 
associated with this incision many young men choose 
chemotherapy as primary treatment for CS I NSGCT 
despite its significant toxicities (3,4). 
Laparoscopic RPLND (L-RPLND) was introduced in 
1992 as an alternative to O-RPLND (5) and was utilized in 
patients with CS I and low volume CS II disease. Compared 
to O-RPLND, L-RPLND resulted in significantly 
decreased morbidity, however, given that the majority of 
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patients undergoing L-RPLND had lower lymph node 
yields (6), and those found to have positive retroperitoneal 
lymph nodes received adjuvant chemotherapy, it was mostly 
considered a staging procedure (7). Additionally, L-RPLND 
is a challenging operation with difficulty accessing the 
lymph nodes posterior to the great vessels and controlling 
vascular bleeding. It was thus limited only to a few centers 
of excellence with expert laparoscopic surgeons. 
Robotic surgery is an alternative minimally invasive 
surgical technique resulting in the benefit of decreased 
surgical morbidity associated with laparoscopic surgery 
while providing improved visualization, instrument 
dexterity and ergonomics. R-RPLND was first performed 
in 2006 (8), and since then, multiple investigators have 
demonstrated it to be a viable and safe surgical approach 
(9-11). With R-RPLND, there is improved capability 
to dissect behind the great vessels and to more easily 
control major bleeding. As experience with R-RPLND has 
improved, it has transformed a minimally invasive approach 
to RPLND from a staging operation to a therapeutic one. 
Indications and staging for R-RPLND
Patients with suspected testicular cancer should routinely 
have tumor markers drawn prior to orchiectomy, 
including alpha fetal protein (AFP), beta-human chorionic 
gonadotropin (B-HCG), and lactate dehydrogenase 
(LDH). Axial imaging of the chest, abdomen, and pelvis is 
performed with computed tomography (CT) scan. Based on 
orchiectomy pathology results, tumor markers, and imaging 
findings, the appropriate clinical stage can be determined.
R-RPLND can be employed as primary treatment 
for patients with tumor marker negative, high-risk, CS I 
NSGCT. Those with pathology specimens demonstrating 
lymphovascular invasion or greater than 50% embryonal 
carcinoma in the orchiectomy specimen are considered 
high risk. Patients with low risk CS I NSGCT are best 
managed with active surveillance. Some investigators are 
also exploring the use of RPLND as primary treatment for 
low-stage seminoma, however, the results of this are yet to 
be determined (12). Patients with tumor marker negative 
CS IIA NSGCT and certain cases of CS IIB NSGCT may 
be eligible for primary treatment with R-RPLND (2). 
Additionally, NSGCT patients with post-chemotherapy 
masses larger than 1 cm and negative tumor markers 
are candidates for R-RPLND (2). Patients with post 
chemotherapy masses obstructing the inferior vena cava 
which may require vascular replacement are best managed 
with an open approach. 
Operative technique and perioperative 
management 
After full pre-operative assessment and appropriate 
patient counseling has been completed, informed 
consent is obtained and if the patient is under 18 years 
of age, parental consent is necessary. Potential risks of 
the procedure that are discussed include major vascular 
injury requiring repair or vascular surgery consultation, 
bowel injury, nephrectomy, deep venous thrombosis with 
pulmonary embolus, lymphatic fluid leakage including 
chylous ascites, and ejaculatory dysfunction. Patients are 
routinely counseled to back sperm prior to R-RPLND. 
Patients undergo a modified bowel preparation with a clear 
liquid diet and magnesium citrate starting 24 hours prior 
to surgery. Induction of general anesthesia is performed 
with deep paralysis to allow for full pneumoperitoneum. 
Mechanical and chemical deep vein thrombosis prophylaxis 
is given with placement of sequential compression 
devices and subcutaneous injection of unfractionated or 
low molecular weight heparin. Perioperative antibiotics, 
typically a cephalosporin, are administered within 
30 minutes of incision time. An orogastric tube is placed to 
decompress the stomach and a urethral catheter is inserted 
to decompress the bladder and keep track of urine output. 
Room set-up and patient positioning
Our technique for R-RPLND is via a supine approach. We 
find that this allows for a complete, bilateral dissection if 
needed. Both the da Vinci (Intuitive Surgical; Sunnyvale, 
CA) Si and Xi platforms can be utilized, although, the Xi 
is our preferred platform as it allows multi-quadrant access 
without the need to redock the robot. 
The patient is placed supine on a full torso gel pad 
which prevents patient movement when placed in the 
Trendelenburg position. Arms are padded and tucked and 
legs are supported. A Veress needle is used to gain entry 
at Palmer’s point (subcostal margin left upper quadrant) 
and establish pneumoperitoneum. If the da Vinci Si model 
is being used, a 12-mm trocar is placed 3–4 cm below the 
umbilicus in the midline. A 0-degree camera is used to place 
the remaining ports under direct vision. An 8-mm right 
robotic port and 4th arm port is placed on the patient’s left 
side and an 8 mm left robotic port is placed on the patient’s 
right side. A 12-mm assistant port is placed between 
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the camera port and the left robotic port (Figure 1). As 
demonstrated in the figure, all arms are placed caudad to the 
level of the umbilicus in an off-set fashion, thus facilitating 
cephalad dissection. There should be at least 7 cm of space 
between ports to prevent external arm collisions. For the 
Xi model, a linear port configuration is utilized using four 
robot 8 mm ports and a 12 mm assistant port (Figure 2). 
These ports are placed at least 6–7 cm apart. A 0-degree 
lens is utilized initially to gain access to the retroperitoneum 
but later switch to a 30-degree down lens during lymphatic 
dissection. We routinely use the Air Seal (Conmed; Utica, 
New York, USA) insufflation device is used to maintain 
pneumoperitoneum at 12 mmHg. The patient is placed in 
20–30 degrees Trendelenburg position to allow the small 
intestine to fall cephalad and the robot is docked. 
The assistant is usually placed on the patient’s right side 
and scrub nurse will be on the patient’s left side. A Mayo 
stand will be positioned between the patient’s legs and will 
hold laparoscopic and robotic instruments commonly used 
throughout the case. If utilizing the da Vinci Si model, 
the robot is brought from the head of the bed over the 
left shoulder. The entire retroperitoneal dissection can 
be performed from this docking location except for the 
removal of the spermatic cord within the inguinal canal. 
Removal of the spermatic cord requires re-docking of the 
da Vinci Si at the end of the case alongside the patient’s 
ipsilateral leg with the ports redirected towards the internal 
inguinal ring. Docking can be from any direction with the 
da Vinci Xi due to the rotating boom, but our routine is 
to dock on the side opposite the bedside assistant. It does 
not need to be redocked to excise the spermatic cord as 
it is designed to allow for extended reach of its arms thus 
providing multi-quadrant access. 
A 0-degree camera is used initially to gain retroperitoneal 
exposure, but is later changed to a 30 degree down lens 
for node dissection. Our instruments of choice include a 
monopolar scissors, a fenestrated bipolar, and a Progasp 
grasper for the 4th arm. If vascular injury is encountered, 
we use robotic needle drivers. Two additional instruments 
that are very helpful for R-RPLND include a robotic clip 
applier, which allows control of lymphatics not able to be 
reached by the assistant, and a robotic vessel sealer, which is 
ideal for controlling lumbar vessels. 
The bedside assistant will have access to a suction-
irrigation device, laparoscopic clip appliers (for both 
titanium and polymer clips), graspers, and laparoscopic 
needle drivers to aid in passing stitches to the surgeon. 
“Rescue stitches” are created beforehand in case urgent 
vascular control is required. We favor a 4-0 polypropylene 
suture cut to 12 cm with a small absorbable clip at the 
end. An endocatch bag is utilized to remove the lymphatic 
specimens as they are freed. 
Dissection technique
Access is gained to the retroperitoneum by incising the 
Figure 1 da Vinci Si port placement configuration. The small “o” 
represents an 8-mm trocar. The large “X” represents a 12-mm 
trocar. 
Figure 2 da Vinci Xi port placement configuration. The small “o” 
represents an 8-mm trocar. The large “X” represents a 12-mm 
trocar. 
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posterior peritoneum just medial to the cecum extending to 
the ligament of Treitz. We typically create a hammock-like 
barrier by suturing both cut ends of the parietal peritoneum 
to the anterior abdominal wall. We typically use a 3-0 
monofilament suture and secure it with polymer clips 
(Figure 3). This, along with the patient’s Trendelenburg 
position, acts to retract the small bowel away from the field, 
allowing visualization of the distal lower retroperitoneum. 
The duodenum is identified and carefully mobilized, if 
needed, and then gently retracted cephalad utilizing the 
Prograsp. This creates the upper retroperitoneal exposure 
needed to allow for a full dissection. 
For both right-sided and left-sided template dissections, 
the ipsilateral renal vessels represent the upper limit 
of dissection (Figure 4). The inferior mesenteric artery 
(typically spared) and the ipsilateral ureteral crossing over 
the common iliac vessels represent, respectively, the inferior 
medial and inferior lateral limits of dissection. A right-sided 
template dissection entails removal of paracaval, precaval, 
retrocaval, interaortocaval, and paraaortic nodal packets. 
A left-sided template dissection includes removal of the 
paraaortic, preaortic, retroaortic, and interaortocaval nodal 
packets. A full, bilateral template dissection combines both 
right-sided and left-sided templates. 
A split-and-roll technique is utilized to remove all lymph 
nodes and allows good access to retrocaval and retroaortic 
nodal tissue. Polymer clips are placed on lymphatic channels 
for node removal and can be placed by the bedside assistant 
or the surgeon via a robotic clip applier. We always ensure 
precise control of the lymphatics crossing over the left renal 
vein as well as the cisterna chyli between the inferior vena 
cava and aorta in order to prevent chylous ascites (Figure 5). 
The inferior mesenteric artery is typically preserved 
but can be sacrificed if needed. We routinely perform a 
nerve-sparing operation to prevent retrograde ejaculation 
especially in post chemotherapy patients requiring a 
bilateral dissection. Sympathetic post-ganglionic nerve 
fibers can be identified at their origin at the sympathetic 
chain. These are traced to the hypogastric plexus overlying 
the distal aorta. Care is taken not to use electrocautery 
along the nerves and nerve fibers to prevent inadvertent 
thermal injury. 
If R-RPLND is being performed for CS I NSGCT, 
typically a unilateral template dissection is performed. 
Lymph nodes are sent for frozen analysis and, if positive, a 
full bilateral template dissection is completed. If R-RPLND 
is being performed for a post-chemotherapy residual mass, 
a full bilateral template dissection is always undertaken 
(Figure 6). All specimens should be placed in endoscopic 
retrieval bags, which are removed at the end of the case. 
Figure 3 Suture suspension of the right peritoneal cut edge to the 
right abdominal wall. 
Figure 4 The renal vessels represent the upper limit of template 
dissection. IVC, inferior vena cava.
Figure 5 Clipping lymphatics, especially those overlying the 
left renal vessels as pictured above, is paramount to preventing a 
chylous leak. IVC, inferior vena cava.
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Spermatic cord excision is lastly performed with 
dissection carried out caudally. If the da Vinci Si is used, re-
docking is needed along the patient’s ipsilateral leg. There 
is no re-docking needed for the da Vinci Xi. Dissection is 
performed out of the internal inguinal ring until sutures 
from the prior radical orchiectomy are seen. These, along 
with the entire cord stump, are removed. 
Post-operative management
Post-operatively, patients are placed on a clear liquid diet, 
which is advanced as tolerated to a low-fat diet (<20 grams 
of fat). This low-fat diet is continued for two weeks after 
the operation to minimize the risk of chylous ascites. 
Chylous ascites, should it develop, is typically managed with 
bowel rest and total parenteral nutrition. Should this not 
resolve, then procedural or operative intervention should 
be considered. Patients should also bank sperm prior to 
surgery in the event of retrograde ejaculation. 
Discussion
As experience with R-RPLND has increased, it has been 
utilized as primary treatment for low-stage NSGCT 
(9,10) and for post-chemotherapy masses (13). Pearce 
et al. (14) had the largest study examining outcomes of 
primary R-RPLND in patients with CS I–IIA NSGCT. 
Six surgeons at four different institutions, over a 5-year 
period, performed R-RPLND on 47 patients, of which 
42 had CS I disease. The median operative time was 
235 minutes and the median estimated blood loss (EBL) was 
50 mL. Risk factors for the retroperitoneal disease included 
lymphovascular invasion and involvement of embryonal 
carcinoma in greater than 40% of the orchiectomy 
specimen. The median lymph node count was 26 nodes and 
the median length of stay (LOS) was one day. Intraoperative 
complications included a vascular injury requiring open 
repair and a pancreatic injury that resolved with drain 
placement and non-operative management. Complications 
within the first 30 days included two Clavien grade I 
complications and two Clavien grade III complications, 
which included a large body-wall hematoma requiring 
transfusion and chylous ascites requiring paracentesis. Eight 
of the 42 patients ultimately had node positive disease, with 
seven or these patients with pN1 disease and the remaining 
patient with pN2 disease. Five of these patients received 
adjuvant chemotherapy with the remaining three managed 
with surveillance. The 2-year recurrence-free survival rate 
was 97% overall (100% in patients not treated with adjuvant 
chemotherapy), however, the median follow-up was only 
6 months, constituting a major limitation of this study (14). 
The largest single institution study was previously 
published by our group in 2016 and examined R-RPLND 
utilizing both the lateral and supine approaches (11). The 
study included 19 patients that underwent 20 procedures, 
16 of which were primary R-RPLND with the remaining 
four post-chemotherapy R-RPLND. Median operative 
time was 293 minutes and median EBL was 50 mL. The 
median lymph node count was 19.5 and the median LOS 
was one day with the vast majority of patients discharged 
within 24 hours of surgery. There was one intraoperative 
complication involving a recognized ureteral transection 
that was primarily repaired without long-term sequelae. 
No patients requiring blood transfusion. There were no 
major post-operative complications although two of the 
patients who underwent post-chemotherapy full template 
R-RPLND did experience retrograde ejaculation. Eight of 
the 19 patients ultimately were found to have pathologic 
stage II disease with three of these patients having teratoma. 
Only two patients received adjuvant chemotherapy, 
including one patient with pathologic stage IIC disease and 
another that developed a lung recurrence four months after 
RPLND. The remaining pathologic stage II patients were 
kept under surveillance with no evidence of recurrence at 
follow-ups of 46, 47, and 91 months, respectively (11). 
Tselos et al. performed a systematic review of 11 studies 
examining a total of 116 patients (15). The mean operative 
Figure 6 View of the great vessels after nodal dissection is 
complete. In the case above, the tumor was noted to be invading 
into the inferior vena cava requiring cavotomy and ultimately 
repair with a 4-0 prolene stitch. IVC, inferior vena cava.
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time was 263 minutes and the median lymph node count 
was 22.3. The complication rate was 8%, with half of these 
designated minor complications (Clavien grade I–II) and 
the other half major complications (Clavien grade III–IV). 
Retrograde ejaculation was seen in 4.5% of patients. The 
median length of stay was 1.3 days and the average follow-
up at 21.2 months demonstrated no evidence of disease 
recurrence (15). 
The length of stay for all R-RPLND studies detailed 
above was better than those reported for O-RPLND 
(ranging from 3 days, at very high-volume institutes, to 
6.6 days) (6,16-18) and for L-RPLND (2.6 to 3.3 days) 
(6,19). Like L-RPLND (204 to 258 min) (6,19), R-RPLND 
has a longer operative time (235 to 293 min) compared 
to O-RPLND (132 min at very high volume institutions, 
otherwise reported 186 to 270 min) (6,16-18).
Intraoperative complication rates have been reported 
for O-RPLND to range from 5–7% (16,17) with a 
6% transfusion rate (17). EBL is typically higher than 
R-RPLND, with reported rates of 184 to 450 mL (6,16-18). 
Post-operative complication rates have been reported as 
high as 24% (17) with some data suggesting an all-comer 
overall complication rate of 33% (6). 
Laparoscopic complication rates have been reported as 
high as 15.6% with a conversion rate of 3.8% (6) with most 
conversion rates due to bleeding and inability to control 
it laparoscopically. Long term oncologic outcomes after 
laparoscopic surgery, as a primary therapeutic modality, 
have been confounded with the high percentage of patients 
who have chemotherapy after positive nodes are discovered 
after surgery (20). The quality of life in patients who had 
L-RPLND, however, has been shown to be significantly 
higher than those patients who underwent O-RPLND (21). 
There have been studies primarily looking at the 
feasibility of R-RPLND for post-chemotherapy patients 
as well. The major challenge with post-chemotherapy 
RPLND s tems  f rom s ign i f i c an t  f i b ro s i s  o f  the 
retroperitoneal mass causing adhesion to the great vessels. 
This creates an environment for possible vascular injury 
that could require urgent control. Singh et al. published 
the largest single institution series for post-chemotherapy 
R-RPLND involving 13 patients. The vast majority of 
these patients had a unilateral modified template dissection 
with a lateral approach. The median operative time was 
200 minutes and median EBL was 120 mL. The median 
lymph node count was 20 and median LOS was four days. 
The only intraoperative complication was an aortic injury 
that was repaired robotically. Post-operatively, four patients 
developed chylous ascites (two of whom required operative 
repair) and five patients developed an ileus. Pathology 
demonstrated that three patients had teratoma and the 
remaining eight had necrosis. There was no evidence of 
disease recurrence at a median follow-up of 23 months (22). 
Overs et al. reviewed 11 post-chemotherapy patients who 
underwent unilateral modified template R-RPLND via a 
lateral approach. Median operative time was 150 minutes 
and median EBL was 120 mL. The median lymph 
node count was seven and the majority of patients 
were discharged on hospital day three. There were no 
intraoperative complications reported. Post-operatively, one 
patient developed chylous ascites that was managed non-
operatively. Over 70% of men retained ejaculatory function. 
Long-term follow-up was only available for six patients 
and none had evidence of recurrence at 24 months (23). 
Both studies highlight the feasibility of performing post-
chemotherapy RPLND robotically. Critics may argue that, 
per NCCN guidelines, a full bilateral template dissection 
should be undertaken in the setting of residual post-
chemotherapy masses (2). A supine approach, as described 
earlier, would allow for better access for a full template 
dissection without the need for re-docking, and should be 
considered.
Operative time for R-RPLND for the above-mentioned 
studies is less than for O-RPLND (226 to 305 min) 
(16,17,24) and is on-par, if not somewhat faster, than for 
L-RPLND (183 to 213 min) (24-26). One has to consider, 
however, that both for R-RPLND and L-RPLND, most of 
these cases involved a modified template dissection on not 
a full bilateral template dissection. EBL was higher in both 
O-RPLND (413 to 1,000 mL) (16,17) with transfusion rates 
ranging from 14.2% to 42% (17,24). Complication rates 
have been reported to range from 12% to 38% (16,17,24). 
L-RPLND had EBL ranging from 260 to 400 mL (25,26) 
with conversion rates reported as high as 11.5% (26), which 
are more than the above mentioned rates for R-RPLND. 
LOS for O-RPLND varied based on institution anywhere 
from 4.8 #to 11.5 days (16,17,24) and 5–6 days for 
L-RPLND (24,26). The complexity of cases varied based 
on institutional experience and operative approach, and thus 
these factors must always be considered when determining 
how to treat patients. 
Conclusions
R-RPLND has developed into a safe and effective 
approach for primary management of low stage NSGCT. 
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In experienced hands, and with judicious patient selection, 
it can also be utilized with good effect for management of 
post-chemotherapy residual NSGCT masses. However, 
for large, bulky residual disease, R-RPLND may prove a 
challenge and one must employ caution in approaching 
these types of cases robotically. As expertise grows, 
techniques will continue to evolve. Our experience has 
demonstrated that a supine approach allows for superior 
retroperitoneal access facilitating full, bilateral template 
dissection. It is the preferred approach for both primary and 
post-chemotherapy R-RPLND. Ultimately, more studies 
with longer-term follow-up directly comparing R-RPLND 
to O-RPLND are needed to effectively compare clinical 
efficacy relative to complications. 
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